All In Biotech

Drug Trial Radar · NCT04659031

A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)

A Phase 1, Open-Label, Single and Multiple Ascending Dose Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM)

Last checked: Nov 19, 2026Latest source record: Feb 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

May 25, 2021

Primary completion

Jan 10, 2025

Study completion Jan 10, 2025

Sponsor

Lead sponsor
Abcuro, Inc.Industry
Sponsor type
Industry
First posted
Dec 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, ascending dose study for adult patients with Inclusion Body Myositis (IBM).

Conditions

  • Inclusion Body Myositis

Interventions

  • ABC008Drug

    ABC008

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of Safety and TolerabilityTime frame: Through Study Completion an average of 28 weeks for SAD (Single Ascending Dose) phase and 52 weeks for MAD (Multiple Ascending Dose) phase]

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Royal Brisbane

    Herston, Australia

  • Perron Institute

    Perth, Australia

  • Royal North Shore Hospital

    Sydney, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.